Prelude Therapeutics Inc (PRLD)
3.65
+0.21
(+6.10%)
USD |
NASDAQ |
Apr 19, 12:31
Prelude Therapeutics Cash from Operations (TTM): -107.06M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -107.06M |
September 30, 2023 | -106.41M |
June 30, 2023 | -101.17M |
March 31, 2023 | -91.97M |
December 31, 2022 | -83.73M |
September 30, 2022 | -86.50M |
June 30, 2022 | -87.84M |
Date | Value |
---|---|
March 31, 2022 | -89.28M |
December 31, 2021 | -83.53M |
September 30, 2021 | -72.68M |
June 30, 2021 | -63.41M |
March 31, 2021 | -52.40M |
December 31, 2020 | -46.18M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-107.06M
Minimum
Dec 2023
-46.18M
Maximum
Dec 2020
-82.47M
Average
-86.50M
Median
Sep 2022
Cash from Operations (TTM) Benchmarks
CEL-SCI Corp | -23.07M |
AIM ImmunoTech Inc | -21.27M |
IGC Pharma Inc | -6.19M |
NovaBay Pharmaceuticals Inc | -4.131M |
Protalix BioTherapeutics Inc | -1.318M |